631 reports of this reaction
4.1% of all ROFLUMILAST reports
#3 most reported adverse reaction
CHRONIC OBSTRUCTIVE PULMONARY DISEASE is the #3 most commonly reported adverse reaction for ROFLUMILAST, manufactured by AstraZeneca Pharmaceuticals LP. There are 631 FDA adverse event reports linking ROFLUMILAST to CHRONIC OBSTRUCTIVE PULMONARY DISEASE. This represents approximately 4.1% of all 15,466 adverse event reports for this drug.
Patients taking ROFLUMILAST who experience chronic obstructive pulmonary disease should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CHRONIC OBSTRUCTIVE PULMONARY DISEASE is moderately reported among ROFLUMILAST users, representing a notable but not dominant share of adverse events.
In addition to chronic obstructive pulmonary disease, the following adverse reactions have been reported for ROFLUMILAST:
The following drugs have also been linked to chronic obstructive pulmonary disease in FDA adverse event reports:
CHRONIC OBSTRUCTIVE PULMONARY DISEASE has been reported as an adverse event in 631 FDA reports for ROFLUMILAST. This does not prove causation, but indicates an association observed in post-market surveillance data.
CHRONIC OBSTRUCTIVE PULMONARY DISEASE accounts for approximately 4.1% of all adverse event reports for ROFLUMILAST, making it one of the most commonly reported side effect.
If you experience chronic obstructive pulmonary disease while taking ROFLUMILAST, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.